Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;16(2):191-7.
doi: 10.1038/nm.2077. Epub 2010 Jan 10.

Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease

Affiliations

Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease

Xuebin Liu et al. Nat Med. 2010 Feb.

Retraction in

Abstract

Interleukin-7 receptor (IL-7R) is genetically associated with susceptibility to multiple sclerosis. Here we describe that IL-7 is essential for survival and expansion of pathogenic T helper type 17 (T(H)17) cells in experimental autoimmune encephalomyelitis (EAE). IL-7 directly expanded effector T(H)17 cells in EAE and human T(H)17 cells from subjects with multiple sclerosis, whereas it was not required for T(H)17 differentiation. IL-7R antagonism rendered differentiated T(H)17 cells susceptible to apoptosis through the inhibition of Janus kinase-signal transducer and activator of transcription-5 (JAK-STAT5) pathway and altered expression of the prosurvival protein Bcl-2 and the proapoptotic protein Bax, leading to decreased severity of EAE. In contrast, T(H)1 and regulatory T (T(reg)) cells were less susceptible to or not affected by IL-7R antagonism in vivo. The selectivity was attributable to minimal expression of IL-7Ralpha in T(reg) cells and correlated with a high level of Socs1 (encoding suppressor of cytokine signaling-1) expression in T(H)1 cells. The study reveals a unique, previously undescribed role of IL-7-IL-7R in T(H)17 cell survival and expansion and has implications in the treatment of autoimmune disease.

PubMed Disclaimer

Comment in

References

    1. Cell. 2002 Apr;109 Suppl:S121-31 - PubMed
    1. J Exp Med. 1994 Nov 1;180(5):1955-60 - PubMed
    1. J Exp Med. 2005 Jan 17;201(2):233-40 - PubMed
    1. J Neurosci Res. 1995 Apr 1;40(5):579-90 - PubMed
    1. Cytokine. 2009 Sep;47(3):149-56 - PubMed

Publication types

MeSH terms